News for Oragenics, Inc. (OGEN)

Oragenics (OGEN) submits protocol for Phase IIa concussion trial in New Zealand. ONP-002, a novel intranasal neurosteroid therapy, targets untreated con

**media[588441]**

**media[570180]**

**media[559397]**

**media[548598]**

U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded...

**media[532875]**

**media[520521]**

Oragenics director Alan Dunton sells $23 in common stock

Shares of Grab Holdings Limited GRAB rose sharply in today's pre-market trading after the company posted better-than-expected results for its third quarter and ...

Shares of DocuSign, Inc. DOCU rose sharply in today's pre-market trading. DocuSign will replace MDU Resources Group Inc. MDU in the S&P MidCap 400, effective p...

OGEN stock touches 52-week low at $0.47 amid sharp annual decline

Oragenics grants stock options to top executives

SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Wednesday. The Dow traded down 0.08% to 40,906.17 while the N...

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.1% on Wednesday. The Dow traded up 0.10% to 40,978.50 while the NASDAQ fell 0....

Shares of GitLab Inc. GTLB rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issue...

Loading... Loading... Shares of XP Inc. XP fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. X...

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.